Introduction

Patent foramen ovale (PFO) is a remnant of fetal circulation present in approximately 25% of the general adult population. In most individuals, this small interatrial communication is hemodynamically insignificant and never discovered. However, when a PFO is identified in a patient who has suffered a cryptogenic stroke (a stroke with no identifiable cause after standard workup), clinicians face a fundamental question: did the PFO cause the stroke, or is it an incidental finding?

This question is far from academic. The answer determines whether the patient may benefit from transcatheter PFO closure (a percutaneous procedure to seal the interatrial defect) or whether standard medical therapy alone is appropriate. Because PFO is so common in the general population, many patients with cryptogenic stroke and a coexisting PFO will have a stroke mechanism unrelated to the PFO. Attributing the stroke to the PFO and proceeding with closure in these patients exposes them to procedural risk without therapeutic benefit.

The Risk of Paradoxical Embolism (RoPE) Score, developed by Kent and colleagues in 2013, was designed to address this clinical dilemma. Using data from 3,023 patients across 12 international databases (the RoPE Study), the investigators identified six clinical characteristics that, when combined into a simple 10-point scoring system, estimate the probability that a PFO detected in the setting of cryptogenic stroke is pathogenic (stroke-related) rather than incidental. The score also predicts the 2-year risk of stroke or transient ischemic attack (TIA) recurrence. Together, these two outputs, the PFO-attributable fraction and the recurrence risk, help clinicians and patients make informed decisions about PFO closure versus medical management.

Historical Background and Development

The association between PFO and cryptogenic stroke was first described in the early 1980s. Case-control studies consistently demonstrated that PFO prevalence was significantly higher in patients with cryptogenic stroke (approximately 40-50%) than in the general population (25%) or in patients with stroke of determined etiology (approximately 20-25%). This epidemiological signal suggested a causal relationship in at least a subset of patients.

Despite this association, early randomized controlled trials of PFO closure (CLOSURE I, 2012; PC Trial, 2013) failed to demonstrate a statistically significant benefit of device closure over medical therapy alone. A major criticism of these trials was that they enrolled heterogeneous populations of cryptogenic stroke patients with PFO, many of whom likely had incidental PFOs unrelated to their stroke. By including patients whose PFOs were bystanders, the treatment effect of closure was diluted.

The RoPE Study was conceived to develop a tool that could distinguish pathogenic from incidental PFOs. Kent and colleagues aggregated individual patient data from 12 component databases of cryptogenic stroke patients who had undergone PFO assessment by transesophageal echocardiography (TEE) or transcranial Doppler (TCD). Using multivariable logistic regression, they identified a set of clinical features that predicted PFO prevalence among cryptogenic stroke patients. The logic was that factors predicting higher PFO prevalence in a cryptogenic stroke population are the same factors associated with PFO-mediated stroke, because they identify patients who lack alternative stroke mechanisms.

The RoPE Score was published in 2013 and quickly became the standard tool for clinical decision-making regarding PFO closure. Subsequent landmark trials (RESPECT long-term follow-up, 2017; CLOSE, 2017; DEFENSE-PFO, 2018) demonstrated that PFO closure was superior to medical therapy in carefully selected patients, and post-hoc analyses confirmed that benefit was concentrated in patients with high RoPE scores, validating the score's intended purpose.

The RoPE Score Components

The RoPE Score consists of six clinical variables totaling a maximum of 10 points. Five are binary variables (each worth 1 point), and one is an age-based variable (worth 0-5 points):

Variable	Criterion	Points
No history of hypertension	Absence of hypertension	+1
No history of diabetes	Absence of diabetes mellitus	+1
No prior stroke or TIA	No previous cerebrovascular event	+1
Non-smoker	No current or recent tobacco use	+1
Cortical infarct on imaging	Superficial/cortical distribution on CT or MRI	+1
Age 18-29	Age-based points	+5
Age 30-39		+4
Age 40-49		+3
Age 50-59		+2
Age 60-69		+1
Age ≥70		0

The total score ranges from 0 to 10. Higher scores indicate a greater likelihood that the PFO is pathogenic and a lower 2-year stroke recurrence risk. Lower scores suggest the PFO is incidental, with a higher recurrence risk driven by conventional vascular mechanisms.

Rationale Behind Each Variable

Absence of Hypertension (+1 point)

Hypertension is the single most important modifiable risk factor for ischemic stroke. Its presence in a patient with cryptogenic stroke suggests that traditional small-vessel or large-artery atherosclerotic disease mechanisms are operative, even if they were not definitively identified during the initial workup. The absence of hypertension removes a major competing stroke mechanism and increases the probability that the PFO is the culprit pathway.

Hypertension is defined according to standard criteria: a documented history of hypertension, use of antihypertensive medications, or blood pressure readings ≥140/90 mmHg. In the RoPE database, patients without hypertension were significantly more likely to have a PFO detected, consistent with the hypothesis that their strokes were more likely PFO-mediated.

Absence of Diabetes (+1 point)

Diabetes mellitus is a potent vascular risk factor that accelerates atherosclerosis, promotes microvascular disease, and increases the risk of ischemic stroke through multiple mechanisms, including carotid artery disease, intracranial atherosclerosis, and hypercoagulability. When diabetes is present, these conventional pathways are plausible explanations for the stroke, reducing the probability that the PFO is responsible. When diabetes is absent, the likelihood of a paradoxical embolism mechanism increases.

No Prior Stroke or TIA (+1 point)

A history of prior stroke or TIA suggests a recurrent cerebrovascular process with an underlying non-PFO mechanism. Recurrent events imply an ongoing pathological process (such as atrial fibrillation, carotid stenosis, or hypercoagulable state) rather than a single embolic event through a PFO. First-ever cryptogenic stroke in a patient without prior cerebrovascular history is more consistent with the paradoxical embolism paradigm: a single venous thrombus traversing the PFO and embolizing to the cerebral circulation.

Non-smoker (+1 point)

Smoking is a well-established risk factor for atherosclerotic vascular disease. It promotes endothelial dysfunction, platelet activation, and accelerated atherogenesis throughout the vascular tree, including the carotid and intracranial arteries. In a smoker with cryptogenic stroke, these vascular changes represent plausible stroke mechanisms even if not captured on standard imaging. The absence of smoking, like the absence of hypertension and diabetes, strips away a competing explanation and shifts the probability toward a PFO-mediated event.

Cortical Infarct on Imaging (+1 point)

The pattern of infarction on brain imaging provides important clues about stroke mechanism. Cortical (superficial) infarcts in the territory of major cerebral arteries are the hallmark of cardioembolic and artery-to-artery embolic stroke, because emboli carried by arterial blood flow tend to lodge at the cortical surface where vessels branch and narrow. In contrast, deep (subcortical, lacunar) infarcts typically result from small-vessel disease caused by hypertension and diabetes.

A cortical infarct pattern in a patient with cryptogenic stroke is more consistent with an embolic mechanism, including paradoxical embolism through a PFO. The RoPE Score awards 1 point for this finding because it shifts the mechanistic probability toward embolism and away from small-vessel disease.

Age (0-5 points)

Age is the most heavily weighted variable in the RoPE Score, contributing up to 5 points. This reflects the profound influence of age on stroke mechanism:

• Young patients (18-29 years): Traditional vascular risk factors (atherosclerosis, atrial fibrillation, small-vessel disease) are uncommon. When a young patient suffers a cryptogenic stroke and is found to have a PFO, the PFO is very likely to be the mechanism, especially in the absence of other risk factors. These patients receive the maximum 5 points.
• Older patients (≥70 years): The prevalence of atherosclerosis, atrial fibrillation (including paroxysmal AF not captured on short-term monitoring), and small-vessel disease increases dramatically with age. A PFO in an elderly patient with cryptogenic stroke is much more likely to be incidental, as the stroke is far more probably attributable to an age-related vascular mechanism that was not identified during the standard workup. These patients receive 0 points for age.

The decremental age scoring creates a smooth gradient that mirrors the epidemiological reality: the younger the patient, the fewer competing stroke mechanisms exist, and the more likely the PFO is pathogenic.

Score Interpretation: PFO-Attributable Fraction and Recurrence Risk

The RoPE Score yields two complementary outputs for each score level:

RoPE Score	PFO-Attributable Fraction	95% CI	2-Year Stroke/TIA Recurrence	95% CI
0-3	0%	0-4%	20%	12-28%
4	38%	25-48%	12%	6-18%
5	34%	21-45%	7%	3-11%
6	62%	54-68%	8%	4-12%
7	72%	66-76%	6%	2-10%
8	84%	79-87%	6%	2-10%
9-10	88%	83-91%	2%	0-4%

The PFO-Attributable Fraction

The PFO-attributable fraction represents the estimated probability that the PFO caused the index stroke in a given patient. It is derived from the difference in PFO prevalence between cryptogenic stroke patients and control populations at each score level. A PFO-attributable fraction of 88% (score 9-10) means that approximately 88% of PFOs found at that score level are estimated to be pathogenic, while only about 12% are incidental. Conversely, a fraction of 0% (score 0-3) means that the PFO prevalence in this group is no higher than expected by chance, implying that essentially all PFOs at this score level are incidental.

The 2-Year Stroke/TIA Recurrence Rate

The recurrence rate exhibits a striking inverse relationship with the RoPE Score: patients with the highest scores (most likely PFO-related stroke) have the lowest recurrence rates, while patients with the lowest scores (most likely incidental PFO) have the highest recurrence rates. This initially counterintuitive finding is explained by the underlying stroke mechanisms:

• High RoPE scores: The stroke was likely caused by a single paradoxical embolus. The recurrence risk is inherently low because the conditions required for paradoxical embolism (simultaneous venous thrombosis, right-to-left shunting, and cerebral arterial lodgment) must coincide again. PFO closure can virtually eliminate this small residual risk.
• Low RoPE scores: The stroke was likely caused by conventional vascular disease (atherosclerosis, occult atrial fibrillation, small-vessel disease). These mechanisms are chronic, progressive, and prone to recurrence. The 2-year recurrence rate of 20% reflects the ongoing burden of vascular risk factors. PFO closure does not address these underlying mechanisms.

This inverse relationship has an important clinical implication: the patients who stand to benefit most from PFO closure (high RoPE scores) are also those at lowest absolute risk of recurrence. The treatment benefit is therefore a relative risk reduction on top of an already low baseline risk, which should be communicated clearly to patients during shared decision-making.

Pathophysiology of Paradoxical Embolism

Understanding the mechanism of paradoxical embolism through a PFO provides essential context for the RoPE Score:

The Patent Foramen Ovale

The foramen ovale is a physiological opening in the interatrial septum that allows oxygenated blood from the placenta to bypass the fetal lungs by shunting from the right atrium to the left atrium. After birth, the increase in left atrial pressure (from the newly functioning pulmonary circulation) presses the septum primum flap against the septum secundum, functionally closing the foramen. In most individuals, these layers fuse permanently during the first few years of life. In approximately 25% of adults, however, fusion is incomplete, leaving a potential communication, the PFO, that can open when right atrial pressure exceeds left atrial pressure.

The Paradoxical Embolism Pathway

Paradoxical embolism occurs through a three-step process:

1. Venous thrombosis: A thrombus forms in the venous system, most commonly in the deep veins of the lower extremities or pelvis (deep vein thrombosis, DVT). Pelvic vein thrombosis and upper extremity DVT (particularly in young patients with thoracic outlet abnormalities) are also recognized sources.
2. Right-to-left shunting: The venous thrombus (or a fragment of it) travels to the right atrium. During a transient elevation of right atrial pressure (Valsalva maneuver, coughing, straining, positive-pressure ventilation), the thrombus crosses the PFO into the left atrium.
3. Arterial embolization: Once in the left atrium, the thrombus enters the systemic arterial circulation and embolizes to the brain (causing stroke) or, less commonly, to other organs (coronary arteries, peripheral arteries, visceral arteries).

Anatomical Features That Increase Risk

Not all PFOs carry equal risk. Certain anatomical features increase the probability of paradoxical embolism:

• Large shunt size: PFOs with a large separation between the septum primum and secundum allow easier passage of thrombi. Shunt size is quantified by the number of microbubbles crossing during contrast echocardiography or by the physical dimensions measured on TEE.
• Atrial septal aneurysm (ASA): An ASA is defined as ≥10-15 mm of excursion of the interatrial septum into either atrium. ASA is present in approximately 2-3% of the general population but is significantly more common in cryptogenic stroke patients with PFO (15-25%). The combination of PFO and ASA carries the highest risk of paradoxical embolism.
• Prominent Eustachian valve or Chiari network: These embryological remnants in the right atrium can direct blood flow from the inferior vena cava preferentially toward the PFO, facilitating right-to-left shunting.
• Hypermobility of the septum primum: Excessive mobility of the flap valve may allow intermittent opening even without sustained right atrial pressure elevation.

The RoPE Score does not directly incorporate these anatomical features, which are assessed separately during the PFO closure evaluation. A high RoPE score combined with high-risk anatomical features provides the strongest indication for closure.

Epidemiology of Cryptogenic Stroke and PFO

• Stroke incidence: Approximately 795,000 strokes occur annually in the United States, of which roughly 87% are ischemic.
• Cryptogenic stroke: After standard workup (brain imaging, vascular imaging, cardiac monitoring, laboratory evaluation), approximately 25-40% of ischemic strokes remain without an identified cause, classified as cryptogenic or "embolic stroke of undetermined source" (ESUS).
• PFO prevalence in cryptogenic stroke: PFO is found in 40-50% of patients with cryptogenic stroke, compared to 25% in the general population and 20-25% in patients with stroke of determined cause.
• Age distribution: The association between PFO and cryptogenic stroke is strongest in patients under 55 years of age. In younger patients, up to 50-60% of cryptogenic strokes are associated with PFO.
• Recurrence rates: Without PFO closure, the annual stroke recurrence rate in cryptogenic stroke patients with PFO ranges from 1-5%, depending on the patient's risk profile. With PFO closure, the recurrence rate decreases to approximately 0.5-1.5% per year in appropriately selected patients.

Diagnostic Workup for Cryptogenic Stroke with PFO

Before applying the RoPE Score and considering PFO closure, a thorough evaluation must exclude alternative stroke etiologies:

Brain Imaging

MRI with diffusion-weighted imaging (DWI) is the preferred modality for characterizing the infarct pattern. A cortical distribution favors an embolic mechanism (and scores a point on the RoPE Score). Subcortical lacunar infarcts suggest small-vessel disease. Multiple infarcts in different vascular territories strongly suggest a proximal embolic source (cardiac or aortic arch).

Vascular Imaging

CT angiography (CTA) or MR angiography (MRA) of the head and neck should evaluate for extracranial and intracranial atherosclerotic stenosis, arterial dissection, and other vascular abnormalities. Significant carotid or intracranial stenosis reclassifies the stroke from cryptogenic to large-artery atherosclerosis.

Cardiac Evaluation

• Electrocardiogram (ECG) and telemetry: To detect atrial fibrillation or flutter, the most common cardiac cause of embolic stroke.
• Prolonged cardiac monitoring: Extended Holter monitoring (14-30 days) or implantable loop recorders can detect paroxysmal atrial fibrillation missed on short-term monitoring. Identifying AF reclassifies the stroke mechanism and eliminates the need for PFO closure.
• Transthoracic echocardiography (TTE): Evaluates for structural cardiac disease (valvular disease, intracardiac thrombus, ventricular wall motion abnormalities).
• Transesophageal echocardiography (TEE): The gold standard for PFO detection and characterization. TEE evaluates shunt size (with agitated saline contrast), the presence of atrial septal aneurysm, and other potential cardiac sources of embolism (left atrial appendage thrombus, aortic arch atheroma).
• Transcranial Doppler (TCD) with bubble contrast: An alternative to TEE for detecting right-to-left shunting. TCD is highly sensitive for detecting any degree of shunting but cannot characterize PFO anatomy.

Laboratory Evaluation

Hypercoagulable workup (antiphospholipid antibodies, Factor V Leiden, prothrombin gene mutation, protein C/S deficiency, antithrombin III deficiency) may be considered, particularly in young patients without traditional risk factors. A positive hypercoagulable state can strengthen the paradoxical embolism hypothesis by explaining the venous thrombosis that initiated the embolic cascade.

Evidence from PFO Closure Trials

The RoPE Score's clinical utility was validated by landmark randomized trials that demonstrated the benefit of PFO closure in selected patients:

CLOSURE I (2012)

The first major randomized trial comparing PFO closure (STARFlex device) to medical therapy in 909 patients with cryptogenic stroke and PFO. The trial showed no significant difference in the primary endpoint (2-year stroke/TIA recurrence). However, CLOSURE I did not use the RoPE Score for patient selection and enrolled a heterogeneous population including many patients with low RoPE scores whose PFOs were likely incidental.

RESPECT (Extended Follow-up, 2017)

The RESPECT trial randomized 980 patients to PFO closure (Amplatzer PFO Occluder) versus medical therapy. Extended follow-up (median 5.9 years) demonstrated a significant reduction in recurrent ischemic stroke with PFO closure (HR 0.55, 95% CI 0.31-0.999). Subgroup analysis showed that benefit was concentrated in patients with large shunts, atrial septal aneurysm, and features consistent with high RoPE scores.

CLOSE (2017)

The CLOSE trial enrolled 663 patients aged 16-60 with cryptogenic stroke and PFO with associated atrial septal aneurysm or large interatrial shunt. PFO closure resulted in zero strokes over a mean follow-up of 5.3 years, compared with a stroke rate of 6.0% in the antiplatelet-only group (HR 0.03, p < 0.001). This trial demonstrated the most dramatic treatment effect and enrolled a population enriched with high RoPE score characteristics.

DEFENSE-PFO (2018)

A Korean trial of 120 patients with cryptogenic stroke, PFO, and high-risk anatomical features. PFO closure reduced the composite endpoint of stroke, vascular death, or major bleeding (HR 0.12, p = 0.013).

Post-hoc Analyses and the RoPE Score

Subsequent meta-analyses and post-hoc analyses of these trials have consistently demonstrated that the benefit of PFO closure is greatest in patients with:

• Higher RoPE scores (particularly ≥7)
• Large PFO shunt size
• Atrial septal aneurysm
• Younger age
• Absence of traditional vascular risk factors

These findings validate the RoPE Score as a clinical enrichment tool: by identifying patients whose PFOs are most likely pathogenic, it selects the population most likely to benefit from closure.

Clinical Application: Step-by-Step

1. Confirm cryptogenic stroke: Ensure that a thorough workup (brain MRI, vascular imaging, cardiac monitoring, echocardiography, laboratory evaluation) has excluded identifiable stroke etiologies. The RoPE Score is only applicable to cryptogenic stroke patients with PFO.
2. Assess the five binary variables: Determine the presence or absence of hypertension, diabetes, prior stroke/TIA, smoking, and cortical infarct. Award 1 point for each favorable characteristic (absence of risk factor, or presence of cortical infarct).
3. Assign age points: Determine the patient's age group and assign the corresponding 0-5 points.
4. Calculate the total score: Sum all points (range 0-10).
5. Interpret the PFO-attributable fraction: Use the score-specific table to determine the estimated probability that the PFO caused the stroke.
6. Assess the 2-year recurrence risk: Note the predicted recurrence rate. Communicate this to the patient in the context of treatment options.
7. Integrate with anatomical features: Combine the RoPE Score with TEE findings (shunt size, ASA) to make a comprehensive assessment. High RoPE score + high-risk anatomy = strongest indication for PFO closure.
8. Multidisciplinary discussion: PFO closure decisions should involve neurology, cardiology, and the patient in a shared decision-making process.

The RoPE Score Paradox

One of the most important and often misunderstood aspects of the RoPE Score is its paradoxical relationship between PFO attribution and recurrence risk:

• Patients with the highest RoPE scores (9-10) have the highest probability that the PFO caused the stroke (88%) but the lowest 2-year recurrence risk (2%).
• Patients with the lowest RoPE scores (0-3) have essentially no probability of PFO-related stroke (0%) but the highest 2-year recurrence risk (20%).

This creates a clinical tension: the patients most likely to benefit from PFO closure have the lowest baseline risk, meaning the absolute risk reduction from closure is small. Conversely, the patients at highest risk of recurrence will not benefit from closure because their PFOs are not the cause of their strokes.

The resolution of this paradox lies in understanding the different stroke mechanisms at each end of the spectrum. High RoPE score patients have PFO-mediated stroke with inherently low recurrence risk; closure provides a small absolute benefit but a large relative benefit. Low RoPE score patients have conventional vascular disease driving high recurrence; their management should focus on aggressive secondary prevention (antihypertensives, statins, antiplatelet or anticoagulant therapy, lifestyle modification) rather than PFO closure.

Medical Therapy vs. PFO Closure

Medical Therapy Options

• Antiplatelet therapy: Aspirin (75-325 mg daily) or clopidogrel (75 mg daily) is the standard initial medical therapy for secondary stroke prevention in patients with cryptogenic stroke and PFO when closure is not pursued.
• Anticoagulation: Some clinicians prefer anticoagulation (warfarin, direct oral anticoagulants) on the rationale that paradoxical embolism involves venous thrombosis, which is better treated with anticoagulants. However, trials have not demonstrated superiority of anticoagulation over antiplatelet therapy in the overall cryptogenic stroke/PFO population, and bleeding risk is higher.

PFO Closure

Transcatheter PFO closure is performed percutaneously via the femoral vein, using devices that occlude the interatrial communication (e.g., Amplatzer PFO Occluder, GORE CARDIOFORM Septal Occluder). The procedure is typically performed under fluoroscopic and echocardiographic guidance and requires general anesthesia or conscious sedation. Patients receive dual antiplatelet therapy (aspirin + clopidogrel) for 1-6 months post-procedure, followed by aspirin alone.

Complications of PFO Closure

• Atrial fibrillation: The most common complication, occurring in 3-6% of patients, typically within the first 30 days. Most cases are self-limiting or responsive to treatment. Persistent AF is rare but clinically significant because it is itself a stroke risk factor.
• Device-related complications: Device embolization, erosion, and thrombus formation are rare (<1%).
• Vascular access complications: Groin hematoma, pseudoaneurysm, arteriovenous fistula at the femoral puncture site.
• Residual shunt: Complete PFO closure is not achieved in all patients. A small residual shunt may persist in 5-15% of cases, though the clinical significance of small residual shunts is uncertain.

Special Considerations

Embolic Stroke of Undetermined Source (ESUS)

The concept of ESUS, proposed by Hart and colleagues in 2014, overlaps significantly with cryptogenic stroke but uses more specific diagnostic criteria (including mandatory vascular imaging, ≥24 hours of cardiac monitoring, and exclusion of lacunar infarcts). Not all ESUS patients have PFO, and not all cryptogenic stroke patients meet the strict ESUS criteria. The RoPE Score was developed in the broader cryptogenic stroke population and has not been separately validated in the ESUS subpopulation, though its principles remain applicable.

Migraine with Aura

PFO has been associated with migraine with aura, and some patients with PFO-related cryptogenic stroke also have a history of migraine. While PFO closure has been shown to reduce migraine frequency in some studies (PRIMA trial), this is not an established indication for closure. The RoPE Score addresses only the stroke indication and should not be used to guide PFO closure for migraine.

Deep Vein Thrombosis and Venous Thromboembolism

A documented DVT or pulmonary embolism concurrent with the stroke significantly strengthens the paradoxical embolism hypothesis, providing direct evidence of a venous thromboembolic source. The RoPE Score does not incorporate DVT status, but the presence of concurrent VTE should be factored into the clinical decision alongside the score.

Provocative Maneuvers

Paradoxical embolism through a PFO requires transient right-to-left shunting, which can be provoked by Valsalva-type maneuvers (straining at stool, heavy lifting, coughing). A history of a provocative event immediately preceding the stroke onset strengthens the suspicion for paradoxical embolism. This information is not captured by the RoPE Score but can be used qualitatively to support the diagnosis.

Strengths of the RoPE Score

• Derived from a large, multinational database: The score was developed using individual patient data from 3,023 patients across 12 databases, providing robust statistical power and external generalizability.
• Simple and practical: Only six readily available clinical variables are needed. No imaging scores, echocardiographic measurements, or laboratory values beyond the initial stroke workup are required for score calculation.
• Dual output: The score simultaneously estimates the PFO-attributable fraction (diagnostic probability) and the 2-year recurrence risk (prognostic value), providing complementary information for clinical decision-making.
• Validated by randomized trial data: Post-hoc analyses of RESPECT, CLOSE, and DEFENSE-PFO confirm that PFO closure benefit concentrates in patients with characteristics associated with high RoPE scores.
• Addresses a genuine clinical need: The score fills a specific diagnostic gap, distinguishing pathogenic from incidental PFOs, that is not addressed by any imaging modality or biomarker.
• Facilitates shared decision-making: By providing a quantitative probability of PFO attribution and a recurrence estimate, the score gives clinicians and patients a concrete framework for discussing treatment options.

Limitations of the RoPE Score

• Does not incorporate PFO anatomy: The score relies exclusively on clinical variables and does not include shunt size, atrial septal aneurysm, Eustachian valve prominence, or other anatomical features that influence the risk of paradoxical embolism. These features must be assessed separately and integrated with the RoPE Score in clinical decision-making.
• Does not account for concurrent DVT/VTE: A documented venous thrombosis at the time of stroke significantly strengthens the paradoxical embolism hypothesis but is not incorporated into the score.
• Limited by the thoroughness of the cryptogenic workup: The RoPE Score assumes that the stroke has been appropriately classified as cryptogenic after adequate investigation. Occult atrial fibrillation detected on prolonged monitoring, subclinical carotid disease, or other missed etiologies can change the diagnostic picture and invalidate the score's assumptions.
• Age weighting may over-simplify: While age is a powerful predictor of stroke mechanism, the 5-point age scale dominates the total score. A healthy 25-year-old with no risk factors and a cortical infarct will always receive a high score (9-10) regardless of other considerations, while a 75-year-old with identical characteristics will score much lower (4-5). Some clinicians argue that the age weighting is too aggressive.
• Does not predict PFO closure benefit directly: The RoPE Score was designed to estimate PFO attribution, not to predict the therapeutic response to closure. Although high RoPE scores correlate with closure benefit in post-hoc analyses, the score was not specifically designed or validated as a treatment-selection tool.
• Binary risk factor assessment: Each vascular risk factor is scored as present or absent, without grading severity. A patient with well-controlled, mild hypertension on a single agent is scored the same as a patient with severe, poorly controlled hypertension on triple therapy.
• Not validated for systemic (non-cerebral) paradoxical embolism: The RoPE Score was derived from stroke patients and has not been validated for paradoxical embolism to other vascular beds (coronary, peripheral, mesenteric).
• Does not include newer biomarkers: Emerging biomarkers (D-dimer, NT-proBNP, atrial cardiopathy markers) and advanced imaging techniques (4D flow MRI for interatrial shunting) are not incorporated into the score.

Clinical Pearls

• The RoPE Score should only be applied to patients with cryptogenic stroke and documented PFO. It is not a screening tool for PFO in the general stroke population or a general stroke risk calculator.
• A high RoPE score indicates that the PFO is likely pathogenic but does not, by itself, mandate PFO closure. The decision should integrate the score with PFO anatomy (shunt size, ASA), patient preference, procedural risk, and the results of prolonged cardiac monitoring to exclude occult atrial fibrillation.
• Always ensure that prolonged cardiac monitoring (≥2-4 weeks, or an implantable loop recorder in select cases) has been performed before attributing a stroke to PFO. Paroxysmal atrial fibrillation is the most common competing diagnosis and changes management entirely.
• The inverse relationship between PFO attribution and recurrence risk is clinically crucial: patients most likely to benefit from PFO closure are those at lowest absolute risk of recurrence. When counseling patients, frame the benefit as a relative risk reduction (e.g., "closure may cut your already low recurrence risk in half") rather than implying a dramatic absolute benefit.
• Patients with low RoPE scores (0-3) have a 20% 2-year recurrence rate driven by conventional vascular mechanisms. These patients need aggressive secondary prevention (blood pressure control, statin therapy, antiplatelet agents, smoking cessation, diabetes management) and continued workup for occult etiologies, not PFO closure.
• The presence of concurrent deep vein thrombosis, a history of Valsalva-type provocation immediately before stroke onset, or a hypercoagulable state strengthens the paradoxical embolism hypothesis and may tip the treatment decision toward closure even in patients with moderate RoPE scores (5-6).
• Post-procedural atrial fibrillation after PFO closure occurs in 3-6% of patients. This is usually transient, but patients should be monitored, as persistent AF is itself a stroke risk factor and would require anticoagulation.
• In clinical practice, PFO closure is most clearly indicated in patients with a RoPE score of ≥7, a large right-to-left shunt, atrial septal aneurysm, age under 60, and a completed workup excluding other etiologies. This profile aligns with the populations that demonstrated the greatest benefit in the CLOSE and RESPECT trials.
• The RoPE Score is a static assessment performed at the time of the index stroke. It does not account for changes over time (new development of hypertension, diabetes, or atrial fibrillation after the index event). Serial reassessment of the patient's vascular risk profile remains important for long-term management.